Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 25, 2015 11:58 AM ET


Company Overview of Altimmune, Inc.

Company Overview

Altimmune, Inc. operates as a clinical stage immunotherapeutic biotechnology company that develops immunotherapeutic products and vaccines to address public health and biodefense needs. It offers NasoVAX, an intranasally administered recombinant influenza vaccine; HepTcell, an immunotherapy for the chronic hepatitis B virus infection; NasoShield, which provides protection after a single intranasal administration; and Oncosyn, an immunotherapeutic in preclinical testing for the treatment of solid cancers. The company also develops products for use in companion and commercial livestock, including cats, dogs, horses, swine, poultry, and aquaculture. It offers immunotherapeutic products for vari...

19 Firstfield Road

Suite 200

Gaithersburg, MD 20878

United States

Founded in 1997





Key Executives for Altimmune, Inc.

Chief Executive Officer, President and Director
Chief Financial Officer
Age: 59
Outside General Counsel and Secretary
Chief Scientific Officer
Compensation as of Fiscal Year 2015.

Altimmune, Inc. Key Developments

Altimmune, Inc. Presents at Ladenburg Thalmann 2015 Healthcare Conference, Sep-29-2015 11:30 AM

Altimmune, Inc. Presents at Ladenburg Thalmann 2015 Healthcare Conference, Sep-29-2015 11:30 AM. Venue: Sofitel Hotel, New York, New York, United States.

Vaxin Inc. Appoints Elizabeth Adkins Czerepak as Chief Financial Officer

Vaxin Inc. strengthened its leadership team by appointing Elizabeth Adkins Czerepak to the newly created position of chief financial officer (CFO). Ms. Czerepak is a finance expert with over 20 years of executive experience in the pharmaceutical, biotech, and venture capital industries. As Vaxin's CFO, she will grow the company's finance organization, oversee M&A activities, and drive interactions with the investor community. A seasoned finance executive, Ms. Czerepak has led a broad range of initiatives at public and privately held companies. As a venture capital investor and board member at Bear Stearns Health Innoventures (BSHI), she played a key role in raising hundreds of millions of dollars in private financings and IPOs, and achieving $537 million and $364 million acquisitions of portfolio companies.

Vaxin Inc. Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 01:50 PM

Vaxin Inc. Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 01:50 PM. Venue: Millennium Broadway Hotel & Conference Center, New York, New York, United States. Speakers: William Enright, Chief Executive Officer, President and Director.

Similar Private Companies By Industry

Company Name Region
GenBase, Inc. United States
CARR Separations Inc. United States
Parallel Solutions, Inc. United States
Bullet Biotechnology, Inc. United States
MDREJUVENA, Inc. United States

Recent Private Companies Transactions

Private Placement
February 17, 2015
February 17, 2015
Immune Targeting Systems (ITS) Limited

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Altimmune, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at